Document is current
Any future updates will be listed below
-
Authors
Williams, Marc J. https://orcid.org/0000-0001-5524-4174
Oliphant, Michael U. J.
Au, Vinci https://orcid.org/0000-0002-3587-6200
Liu, Cathy
Baril, Caroline
O’Flanagan, Ciara
Lai, Daniel https://orcid.org/0000-0001-9203-6323
Beatty, Sean https://orcid.org/0000-0001-6819-7071
Van Vliet, Michael
Yiu, Jacky CH https://orcid.org/0009-0007-4273-0051
O’Connor, Lauren
Goh, Walter L.
Pollaci, Alicia
Weiner, Adam C. https://orcid.org/0000-0002-5968-3606
Grewal, Diljot
McPherson, Andrew
Norton, Klarisa
Moore, McKenna
Prabhakar, Vikas
Agarwal, Shailesh
Garber, Judy E.
Dillon, Deborah A.
Shah, Sohrab P. https://orcid.org/0000-0001-6402-523X
Brugge, Joan S. https://orcid.org/0000-0002-2547-4814
Aparicio, Samuel https://orcid.org/0000-0002-0487-9599
- License Information
-
More Information
Article History
Received: 10 May 2024
Accepted: 15 October 2024
First Online: 20 November 2024
Competing interests
: J.S.B. is a scientific advisory board (SAB) member of Frontier Medicines. D.A.D. is on the SAB for Oncology Analytics, has consulted for Novartis and receives research support from Canon. J.E.G. is a paid consultant for Helix and an uncompensated consultant for Konica Minolta and Earli. S.P.S. has consulted for AstraZeneca and has received funding from Bristol Meyers Squibb. S. Aparicio is cofounder and shareholder of Genome Therapeutics, uncompensated advisor to Chordia Therapeutics and advisor to Sangamo Therapeutics. The other authors declare no competing interests.
